Dr. James Schultz, M.D
Family Medicine (Family Medicine Physician)
460 N Elm St
Escondido, CA 92025
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
At a glance
- Medical school
- University of California, Geffen School of Medicine (1985)
- Years since graduation
- 41
- In the NPI registry since
- 2006
Licensed in California since 1987, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1985Medical school: University of California, Geffen School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
CA license G61829 (first issued 1987; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Neighborhood Healthcare (150 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Atorvastatin Calcium Other prescribers in Escondido, CA | 54 |
| Lisinopril Other prescribers in Escondido, CA | 34 |
| Gabapentin Other prescribers in Escondido, CA | 23 |
| Amlodipine Besylate Other prescribers in Escondido, CA | 20 |
| Tamsulosin Hcl Other prescribers in Escondido, CA | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 4 payments worth $1,055 in total to this clinician.
| Eli Lilly and Company | $1,055 |
|---|
| Travel and Lodging | $1,055 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company Sep 8, 2025 | Travel and Lodging travel to HOUSTON, CA · in-kind | $293 |
| Eli Lilly and Company Oct 22, 2025 | Travel and Lodging travel to HOUSTON, CA · in-kind | $268 |
| Eli Lilly and Company Oct 22, 2025 | Travel and Lodging travel to HOUSTON, CA · in-kind | $248 |
| Eli Lilly and Company Sep 8, 2025 | Travel and Lodging travel to HOUSTON, CA · in-kind | $248 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 5 companies. The companies reported $659,255 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP)
Abbott Laboratories - Study name not reported
Novo Nordisk As - Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Eli Lilly and Company · Active, not recruiting · NCT06297603 - A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Eli Lilly and Company · Completed · NCT06045221 - A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Eli Lilly and Company · Completed · NCT05971940 - SUBLOCADE Long-term Outcomes
Indivior Inc. · Completed · NCT05860959 - A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients…
Alnylam Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.